HOSPITAL UNIVERSITARIO RUBER
Departamento
Medical University of Vienna
Viena, AustriaPublicaciones en colaboración con investigadores/as de Medical University of Vienna (17)
2023
-
Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023
Annals of Oncology
-
Understanding the activity of antibody–drug conjugates in primary and secondary brain tumours
Nature Reviews Clinical Oncology, Vol. 20, Núm. 6, pp. 372-389
2022
-
Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer
Cancer Treatment Reviews, Vol. 111
2021
-
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study
Annals of Oncology, Vol. 32, Núm. 12, pp. 1571-1581
-
Anthracyclines strike back: Rediscovering non‐pegylated liposomal doxorubicin in current therapeutic scenarios of breast cancer
Cancers, Vol. 13, Núm. 17
-
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer ☆
Annals of Oncology, Vol. 32, Núm. 12, pp. 1475-1495
-
Expected medium- And long-term impact of the COVID-19 outbreak in oncology
JCO Global Oncology, Vol. 7, pp. 162-172
-
Human Microbiota and Breast Cancer—Is There Any Relevant Link?—A Literature Review and New Horizons Toward Personalised Medicine
Frontiers in Microbiology, Vol. 12
-
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group
npj Breast Cancer, Vol. 7, Núm. 1
2020
-
ASCO 2020
Breast Care
-
ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer
ESMO Open, Vol. 5
-
Oncological care organisation during COVID-19 outbreak
ESMO Open, Vol. 5, Núm. 4
2019
-
Breast cancer
Nature Reviews Disease Primers, Vol. 5, Núm. 1
2016
-
Adjuvant bisphosphonates in early breast cancer: Consensus guidance for clinical practice from a European Panel
Annals of Oncology, Vol. 27, Núm. 3, pp. 379-390
-
Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer
Annals of Oncology, Vol. 27, Núm. 11, pp. 2046-2052
2010
-
Benefits of vaccinating young adult women with a prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine
Vaccine, Vol. 28, Núm. 51, pp. 8065-8072